JNJ) has become the latest large-cap biopharma company to strike a deal with the U.S. government to supply the coronavirus vaccine it has in development.
Ad26.COV2.S, the SARS-CoV-2 vaccine being developed by its Janssen unit, once it is approved or issued Emergency Use Authorization by the FDA.” data-reactid=”20″>What Happened: J&J said Wednesday that it has entered into an agreement with the U.S. government for large-scale domestic manufacturing and supply of 100 million doses of Ad26.COV2.S, the SARS-CoV-2 vaccine being developed by its Janssen unit, once it is approved or issued Emergency Use Authorization by the FDA.
The agreement also provides for the company receiving $1 billion from BARDA and the U.S. Department of Defense.
The U.S. government may also purchase incremental doses of the vaccine under a subsequent agreement, J&J said.
The company said Ad26.COV2.S will be provided on a global not-for-profit basis for emergency pandemic use.
sign up for our coronavirus newsletter.” data-reactid=”28″>Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter.
agreements in place to supply vaccines to the government.” data-reactid=”29″>The Pfizer Inc. (NYSE: PFE)/BioNTech SE – ADR (NASDAQ: BNTX) combine, AstraZeneca plc (NYSE: AZN)/Oxford University and Sanofi SA (NASDAQ: SNY)/GlaxoSmithKline plc (NYSE: GSK) have also agreements in place to supply vaccines to the government.
The company said it is on track to meet its goal of supplying over 1 billion doses of the vaccine globally through the course of 2021, provided it is found safe and effective.
View Article Origin Here